Oxytocin
FDA-approved neuropeptide — drives bonding, trust, and social cognition. Intranasal research shows real anxiolytic and pro-social effects.
Research facts
| Half-life | ~1–6 minutes (IV) / longer intranasal CNS effect |
|---|---|
| Route | Intranasal / IV / IM |
| Typical dose | 24–40 IU intranasal (research) |
| Frequency | As needed or 1–3× daily in research |
| Solvent | Commercial nasal spray |
| pH | N/A |
| Stability | Refrigerated |
Mechanism of action
Oxytocin is a nonapeptide produced in the hypothalamic paraventricular and supraoptic nuclei. It binds the oxytocin receptor (OXTR) distributed throughout the brain (amygdala, hippocampus, prefrontal cortex) and peripheral tissues. Central effects include modulation of social behaviour, fear extinction, trust, maternal bonding, and sexual function. Peripherally, it stimulates uterine contractions (FDA-approved for labour induction as Pitocin) and milk ejection. Intranasal oxytocin bypasses the blood-brain barrier via the olfactory and trigeminal nerve routes, achieving CNS delivery.
Documented effects (research-model)
- FDA-approved for labour induction and postpartum haemorrhage (Pitocin)
- Social cognition and prosocial behaviour enhancement in RCTs
- Anxiolytic effects in social anxiety disorder studies
- Appetite and eating behaviour modulation
- Pain perception modulation
- PTSD and social phobia research
Research protocols
| Protocol | Dose | Frequency | Cycle | Vial |
|---|---|---|---|---|
| Research | 24–40 IU intranasal | Single dose before social engagement or 1–3× daily | As needed or short cycles | Nasal spray preparation |
Research context only. Not medical advice. Consult a qualified healthcare professional before any protocol decision.
Synergies
- Selank MODERATE
Selank (general anxiolysis, serotonin) + Oxytocin (social fear reduction, bonding). Combined social anxiety and prosocial stack.
Myths & misconceptions
Evidence gaps
- Intranasal bioavailability and CNS penetration vary significantly across formulations and individuals.
- Effects are highly context-dependent — not always consistently positive.
- Long-term intranasal use effects on endogenous oxytocin production not characterised.
Safety notes
Intranasal generally well-tolerated. IV form requires medical supervision. Mild headache most common side effect. Water retention with high-dose IV use. Avoid in conditions requiring sodium restriction. Research context for intranasal use.
Biomarkers to monitor
Primary-source citations
- PMID 16094029 — Oxytocin increases trust in humans (Nature. 2005)
Frequently asked
What is Oxytocin?
Oxytocin (Oxytocin — The "Bonding" Neuropeptide) is a research compound classified in our library as Tier A — Reproducible human RCT data.. FDA-approved neuropeptide — drives bonding, trust, and social cognition. Intranasal research shows real anxiolytic and pro-social effects.
What is the evidence tier for Oxytocin?
We classify Oxytocin as Tier A: Reproducible human RCT data. See our full peptide evidence tiers explainer for how we assign S/A/B/C/D.
What is the research dose of Oxytocin?
For Oxytocin, typical research dose is 24–40 IU intranasal (research), route is Intranasal / IV / IM, half-life is ~1–6 minutes (IV) / longer intranasal CNS effect. Protocols vary by research goal — see the protocols section on this page for standard and advanced dosing schedules. Research use only, not medical advice.
Is Oxytocin safe?
Intranasal generally well-tolerated. IV form requires medical supervision. Research context only — no compound on this site is approved for human therapeutic use unless explicitly noted.